Cited 16 times in
Validation of a novel molecular RPA classification in glioblastoma (GBM-molRPA) treated with chemoradiation: A multi-institutional collaborative study
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김세훈 | - |
dc.contributor.author | 서창옥 | - |
dc.contributor.author | 장종희 | - |
dc.contributor.author | 김나리 | - |
dc.date.accessioned | 2019-01-15T17:02:08Z | - |
dc.date.available | 2019-01-15T17:02:08Z | - |
dc.date.issued | 2018 | - |
dc.identifier.issn | 0167-8140 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/166770 | - |
dc.description.abstract | BACKGROUND AND PURPOSE: A novel molecular recursive partitioning analysis classification has recently been reported integrating the MGMT promoter methylation (MGMTmeth) and IDH1 mutation (IDH1mut) status for glioblastoma (GBM-molRPA) patients treated with temozolomide-based chemoradiation. The current study was initiated to validate the model in a multi-institutional study. MATERIALS AND METHODS: Four-hundred seventy-one newly diagnosed GBM patients (validation cohort) were allocated to classes I-III of the previously reported GBM-molRPA model. Of the patients, 15.7%, 56.1%, and 28.2% patients were GBM-molRPA class I, II, and III, respectively. MGMTmeth and IDH1mut were observed in 32.3 and 8.8% of patients, respectively. In the training plus validation cohort of 692 patients, 16.2%, 60.8%, and 23.0% patients were class I, II, and III, respectively. RESULTS: The median follow-up for survivors and the median survival (MS) of patients was 23.3 and 18.4 months, respectively. The MS for GBM-molRPA class I, II, and III was 49.7 (95% CI, 22.8-76.6), 19.2 (95% CI, 16.2-22.1), and 13.8 months (95% CI, 11.8-15.4) (P < .001 for all comparisons) in the validation cohort. In the training plus validation cohort, the MS was 58.5 (95% CI, 40.7-76.3), 21. (95% CI, 18.6-23.3), and 14.3 months (95% CI, 12.5-16.1) (P < .001 for all comparisons) for class I, II, and III, respectively. CONCLUSION: The GBM-molRPA is a valid model. This GBM-molRPA classification can be useful in clinics and guiding patient stratification in future clinical trials. | - |
dc.description.statementOfResponsibility | restriction | - |
dc.language | English | - |
dc.publisher | Elsevier Scientific Publishers | - |
dc.relation.isPartOf | RADIOTHERAPY AND ONCOLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.title | Validation of a novel molecular RPA classification in glioblastoma (GBM-molRPA) treated with chemoradiation: A multi-institutional collaborative study | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Pathology (병리학교실) | - |
dc.contributor.googleauthor | Chan Woo Wee | - |
dc.contributor.googleauthor | Il Han Kim | - |
dc.contributor.googleauthor | Chul-Kee Park | - |
dc.contributor.googleauthor | Jin Wook Kim | - |
dc.contributor.googleauthor | Yun-Sik Dho | - |
dc.contributor.googleauthor | Fumiharu Ohka | - |
dc.contributor.googleauthor | Kosuke Aoki | - |
dc.contributor.googleauthor | Kazuya Motomura | - |
dc.contributor.googleauthor | Atsushi Natsume | - |
dc.contributor.googleauthor | Nalee Kim | - |
dc.contributor.googleauthor | Chang-Ok Suh | - |
dc.contributor.googleauthor | Jong Hee Chang | - |
dc.contributor.googleauthor | Se Hoon Kim | - |
dc.contributor.googleauthor | Won Kyung Cho | - |
dc.contributor.googleauthor | Do Hoon Lim | - |
dc.contributor.googleauthor | Do-Hyun Nam | - |
dc.contributor.googleauthor | Jung Won Choi | - |
dc.contributor.googleauthor | In Ah Kim | - |
dc.contributor.googleauthor | Chae-Yong Kim | - |
dc.contributor.googleauthor | Young-Taek Oh | - |
dc.contributor.googleauthor | Oyeon Cho | - |
dc.contributor.googleauthor | Woong-Ki Chung | - |
dc.contributor.googleauthor | Sung-Hwan Kim | - |
dc.contributor.googleauthor | Eunji Kim | - |
dc.identifier.doi | 10.1016/j.radonc.2018.09.001 | - |
dc.contributor.localId | A00610 | - |
dc.contributor.localId | A01919 | - |
dc.contributor.localId | A03470 | - |
dc.relation.journalcode | J02597 | - |
dc.identifier.eissn | 1879-0887 | - |
dc.identifier.pmid | 30236994 | - |
dc.identifier.url | https://www.sciencedirect.com/science/article/pii/S0167814018334686 | - |
dc.subject.keyword | Glioblastoma | - |
dc.subject.keyword | IDH1 | - |
dc.subject.keyword | MGMT | - |
dc.subject.keyword | Recursive partitioning analysis | - |
dc.subject.keyword | Validation | - |
dc.contributor.alternativeName | Kim, Se Hoon | - |
dc.contributor.affiliatedAuthor | 김세훈 | - |
dc.contributor.affiliatedAuthor | 서창옥 | - |
dc.contributor.affiliatedAuthor | 장종희 | - |
dc.citation.volume | 129 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 347 | - |
dc.citation.endPage | 351 | - |
dc.identifier.bibliographicCitation | RADIOTHERAPY AND ONCOLOGY, Vol.129(2) : 347-351, 2018 | - |
dc.identifier.rimsid | 58038 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.